Search
What data can tell you about amorphous drug formulation
To confirm amorphization and assess stability, researchers use a combination of analytical tools:
- DSC (Differential Scanning Calorimetry) reveals thermal transitions. A missing melting peak often indicates an amorphous form.
- XRD (X-ray Diffraction) detects crystallinity through diffraction patterns.
- SEM (Scanning Electron Microscopy) visualizes surface structure, confirming physical dispersion post-TSE. These tools help correlate process parameters like SME to the quality of the resulting amorphous product.
Before (crystalline particles) → TSE → After (amorphous dispersion)
Recrystallization: What to watch for
Amorphous forms are energetically unstable and can recrystallize under stress; this might happen during storage, handling, or downstream processing. Recrystallization not only affects performance but can raise regulatory red flags. Stability planning involving monitoring and testing is essential:
- Monitoring with DSC and XRD at multiple time points
- Stress-testing under humidity and heat
- Choosing excipients that stabilize the amorphous phase
- Using SME data to balance transformation and degradation risk
From analysis to action
Solid-state analytics aren’t just for lab confirmation—they’re crucial for tech transfer, regulatory submissions, and long-term product success. Establishing a clear link between process variables like SME and measurable outcomes like crystallinity reduction builds confidence for scale-up.
- DSC and XRD confirm amorphization effectiveness.
- SEM verifies surface morphology changes post-TSE.
- SME metrics guide consistent, reproducible runs.
Bring your drug formulation to life
You’ve seen how dry amorphization works and how to validate your results. Now it’s time to bring those insights into drug formulation development.
For Research Use Only. Not for use in diagnostic procedures.